Group 1 - The core viewpoint of the news is the strategic partnership between Huajian Medical and Renhe Pharmaceutical's subsidiary to establish the world's first OTC-focused RWA exchange in the U.S. [1] - This collaboration is a key step in Huajian Medical's "ETHK blockchain financial ecosystem strategy" and aims to create a replicable model to validate the feasibility and potential of this innovative approach [1][2] - Huajian Medical will provide compliance operational support through ETHK Inc, while Huajian Digital Industry Development (Shenzhen) Co., Ltd. will handle technology development [1] Group 2 - Renhe Pharmaceutical, a leading player in China's OTC market, aims to revitalize its brand and intangible assets through this partnership, especially after facing revenue declines of 16.46% and net profit drops of 13.87% in the first half of the year [1] - The collaboration is expected to generate significant technical service revenue for Huajian Medical and validate its light-asset, replicable empowerment model [2] - The "ETHK global RWA exchange" model is designed to connect the industry and financial sectors, providing asset selection, structural design, compliance issuance, and liquidity management services [2]

Core Viewpoint - Hong Kong-listed Huajian Medical experienced a recovery in share price after a significant drop of over 10% in the morning session, following the announcement of a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1] Group 1 - Huajian Medical's share price fell more than 10% in the morning session before turning positive in the afternoon [1] - The company announced a strategic cooperation with Renhe International to develop a vertical RWA exchange for OTC drugs in the U.S. [1] - This partnership aims to create a dedicated platform for the OTC drug market, indicating a significant move within the pharmaceutical industry [1]

Group 1 - The company has announced a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1]

與 仁 和 藥 業（000650.SZ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 全資附屬公司仁和國際達成重大戰略合作 與 仁 和 藥 業（000650.SZ）間 接 全 資 附 屬 公 司 仁 和 國 際 達 成 重 大 戰 略 合 作，於 美 國 共 同 籌 建 全 球 首 家 非 處 方 藥（OTC）垂 直 領 域RWA交 易 所。 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、前 言：ETHK生態戰略的系統性深化 茲提述本公司日期為2025年 ...